Generic Antivert Availability
Antivert is a brand name of meclizine, approved by the FDA in the following formulation(s):
ANTIVERT (meclizine hydrochloride - tablet; oral)
-
Manufacturer: PFIZER
Approved Prior to Jan 1, 1982
Strength(s): 12.5MG [RLD] [AA], 25MG [RLD] [AA] -
Manufacturer: PFIZER
Approval date: January 20, 1982
Strength(s): 50MG [RLD] [AA]
Has a generic version of Antivert been approved?
Yes. The following products are equivalent to Antivert:
meclizine hydrochloride tablet; oral
-
Manufacturer: AMNEAL PHARMS
Approval date: February 23, 2011
Strength(s): 12.5MG [AA], 25MG [AA], 50MG [AA] -
Manufacturer: EPIC PHARMA LLC
Approval date: April 13, 2012
Strength(s): 12.5MG [AA], 25MG [AA] -
Manufacturer: JUBILANT CADISTA
Approval date: June 4, 2010
Strength(s): 12.5MG [AA], 25MG [AA] -
Manufacturer: MYLAN PHARMS INC
Approval date: September 17, 2012
Strength(s): 12.5MG [AA], 25MG [AA], 50MG [AA] -
Manufacturer: PAR PHARM
Approved Prior to Jan 1, 1982
Strength(s): 12.5MG [AA], 25MG [AA] -
Manufacturer: PAR PHARM
Approval date: March 31, 1988
Strength(s): 50MG [AA] -
Manufacturer: SANDOZ
Approval date: May 22, 1989
Strength(s): 12.5MG [AA], 25MG [AA] -
Manufacturer: VINTAGE PHARMS
Approval date: January 30, 1997
Strength(s): 12.5MG [AA], 25MG [AA] -
Manufacturer: WATSON LABS
Approved Prior to Jan 1, 1982
Strength(s): 25MG [AA]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Antivert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Antivert.
See also...
- Antivert Consumer Information (Drugs.com)
- Antivert Consumer Information (Wolters Kluwer)
- Antivert Consumer Information (Cerner Multum)
- Meclizine Consumer Information (Drugs.com)
- Meclizine Consumer Information (Wolters Kluwer)
- Meclizine chewable tablets Consumer Information (Wolters Kluwer)
- Meclizine Consumer Information (Cerner Multum)
- Meclizine Hydrochloride AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AA | Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved. |


